Tafluprost is well tolerated in OHT eyes

Article

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT).

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT), reveals an investigation in the British Journal of Ophthalmology.

Dr Elena Milla and her team, Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Barcelona, Spain, conducted a prospective non-interventional, multicentre, observational study on 134 patients. Follow-ups were completed at baseline and one and three months post-treatment.

Five ocular surface symptoms were evaluated as absent, mild, moderate and severe. Tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus were all assessed in each patient.

A significant improvement in all symptoms was seen in 53% of patients with OHT. This included stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation three months after treatment.

All signs except the Schirmer test results improved in the OHT patients. In the glaucomatous eyes the keratitis, hyperaemia and tear meniscus improved at one and three months post-treatment.

Preservative-free tafluprost is a well-tolerated hypotensive agent that can be used to treat naïve eyes and eyes with ocular surface problems.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.